Abbott to Acquire Exact Sciences, Expanding Cancer Diagnostics Leadership | March 2026
- Abbott (NYSE: ABT) is set to finalize its acquisition of Exact Sciences on Monday, March 23, 2026, marking a significant expansion into the rapidly growing cancer screening and...
- The acquisition positions Abbott to lead in a sector experiencing increased demand, fueled by rising cancer incidence worldwide and a growing emphasis on early detection.
- “Proactively shaping the portfolio to anticipate future medical needs while building long-term shareholder value remains at the core of our strategic framework,” said Robert B.
Abbott to Complete Exact Sciences Acquisition on Monday, Expanding Cancer Diagnostics Portfolio
Abbott (NYSE: ABT) is set to finalize its acquisition of Exact Sciences on , marking a significant expansion into the rapidly growing cancer screening and diagnostics market. The deal, initially announced in November 2025, has received all necessary regulatory clearances, according to a statement released by Abbott on .
The acquisition positions Abbott to lead in a sector experiencing increased demand, fueled by rising cancer incidence worldwide and a growing emphasis on early detection. Exact Sciences brings a portfolio of established and emerging cancer diagnostics, including Cologuard®, a leading non-invasive colorectal cancer screening test, and Oncotype DX®, used to personalize breast cancer treatment decisions. The addition of Oncodetect® and Cancerguard® further strengthens Abbott’s offerings in molecular residual disease testing and multi-cancer early detection, respectively.
“Proactively shaping the portfolio to anticipate future medical needs while building long-term shareholder value remains at the core of our strategic framework,” said Robert B. Ford, chairman and chief executive officer of Abbott. “The addition of Exact Sciences enhances Abbott’s growth profile and strengthens our leadership in diagnostics. This transaction brings a powerful new platform in cancer screening and diagnostics into Abbott, advancing our mission to make care more accessible and give people more control over their health.”
The strategic fit is particularly notable given the size and growth trajectory of the cancer screening and precision oncology diagnostics segments. Abbott anticipates the acquisition will add approximately $3 billion in incremental sales in 2026 and contribute approximately 0.5% to the company’s overall sales growth for the year. The combined entity will operate within the $60 billion U.S. Market for cancer screening and precision oncology diagnostics.
While the deal is expected to be financially beneficial, Abbott anticipates a dilution of approximately $0.20 in adjusted earnings per share (EPS) for 2026. However, the company believes the long-term growth potential and strategic advantages outweigh this short-term impact.
The acquisition comes at a time when early cancer detection is gaining prominence as a key strategy in improving patient outcomes. The technologies offered by Exact Sciences allow for earlier diagnosis, more informed treatment decisions, and improved monitoring for cancer recurrence – all critical components of modern cancer care. Abbott’s existing diagnostics infrastructure and global reach are expected to accelerate the adoption and accessibility of these innovative tests.
Investors will be watching closely to see how Abbott integrates Exact Sciences’ operations and realizes the anticipated synergies. The successful combination of these two companies could significantly reshape the landscape of cancer diagnostics and contribute to advancements in preventative healthcare.